Last reviewed · How we verify
RDEA594
At a glance
| Generic name | RDEA594 |
|---|---|
| Sponsor | Ardea Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment (PHASE4)
- Post-Authorisation Safety Study of Lesinurad
- Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence. (PHASE1)
- Lesinurad and Febuxostat Combination Extension Study in Gout (PHASE3)
- Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence (PHASE1)
- Allopurinol Combination Study (PHASE2)
- Lesinurad and Allopurinol Combination Extension Study in Gout (PHASE3)
- Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RDEA594 CI brief — competitive landscape report
- RDEA594 updates RSS · CI watch RSS
- Ardea Biosciences, Inc. portfolio CI